glucose-dependent insulinotropic polypeptide

glucose-dependent insulinotropic polypeptide is a gastrointestinal hormone produced by K cells located primarily in the duodenum and jejunum of the small intestine. It is a member of the glucagon secretin family of hormones and plays a significant role in the enteroinsular axis, the hormonal link between the gut and the endocrine pancreas. Its secretion is stimulated by the ingestion of nutrients, particularly fatty acids and monosaccharides like glucose.

Structure and synthesis

Glucose-dependent insulinotropic polypeptide is synthesized as a preprohormone consisting of 153 amino acids. This precursor undergoes proteolytic cleavage to yield the biologically active 42-amino-acid peptide. The mature hormone shares structural homology with other members of the secretin family, including glucagon-like peptide-1 and vasoactive intestinal peptide. Its gene is located on chromosome 17 in the human genome. The primary sites of synthesis are the K cells, which are enteroendocrine cells scattered among the epithelial cells lining the mucosa of the proximal small intestine.

Physiological function

The primary physiological role of glucose-dependent insulinotropic polypeptide is to augment glucose-stimulated insulin secretion from the beta cells of the pancreatic islets, a phenomenon known as the incretin effect. This action is highly glucose-dependent, meaning it is potent only when blood glucose levels are elevated, such as after a meal. Beyond its insulinotropic effect, it also inhibits gastric acid secretion and modulates gastric emptying, contributing to the ileal brake mechanism. Furthermore, it has been shown to promote lipid accumulation in adipose tissue through stimulation of lipoprotein lipase.

Role in metabolism

In carbohydrate metabolism, glucose-dependent insulinotropic polypeptide significantly enhances postprandial insulin release, thereby facilitating glucose uptake into peripheral tissues like skeletal muscle and adipose tissue. It also exerts effects on lipid metabolism by promoting fatty acid incorporation into adipocytes. Studies, including those from the Joslin Diabetes Center, indicate it may play a role in bone metabolism by affecting osteoblast activity. Its actions are integrated with those of glucagon-like peptide-1, though it has a lesser effect on inhibiting glucagon secretion from pancreatic alpha cells.

Pathophysiological significance

Altered secretion or action of glucose-dependent insulinotropic polypeptide is implicated in several metabolic disorders. In type 2 diabetes mellitus, the incretin effect is diminished, a state referred to as incretin deficiency; however, the hormone's insulinotropic effect is also significantly blunted. Research from institutions like the University of Copenhagen suggests its role may be less impaired than that of glucagon-like peptide-1. Conversely, its lipogenic actions are thought to contribute to obesity and metabolic syndrome. Its receptor is a G protein-coupled receptor expressed in various tissues including pancreas, adipose tissue, bone, and the central nervous system.

Therapeutic applications

Given its physiological role, glucose-dependent insulinotropic polypeptide has been investigated as a therapeutic target. However, unlike glucagon-like peptide-1 receptor agonists such as liraglutide and semaglutide, its native form is rapidly degraded by the enzyme dipeptidyl peptidase-4. Therapeutic strategies have therefore focused on developing dipeptidyl peptidase-4 inhibitors, like sitagliptin and saxagliptin, which prolong the activity of both endogenous incretin hormones. Novel approaches include the development of dual agonists targeting both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, with tirzepatide receiving approval from the U.S. Food and Drug Administration.

Category:Gastrointestinal hormones Category:Peptide hormones Category:Incretins